|
2024
|
Invention
|
Sustained-release dosage forms of ruxolitinib.
The present invention relates to sustained-releas... |
|
|
Invention
|
Ruxolitinib for the treatment of prurigo nodularis.
This disclosure relates to ruxolitinib, or a... |
|
|
Invention
|
Solid forms of jak inhibitor and process of preparing the same.
The present disclosure is relate... |
|
|
Invention
|
Solid forms of an fgfr inhibitor and processes for preparing the same.
The present disclosure re... |
|
|
Invention
|
Bicyclic dgk inhibitors.
The present application provides bicyclic compounds that modulate the a... |
|
|
Invention
|
Bicyclic dgk inhibitors. The present application provides bicyclic compounds that modulate the ac... |
|
|
Invention
|
Bicyclic heterocycles as mrgprx2 antagonists. The present disclosure relates to bicyclic heterocy... |
|
|
Invention
|
Process of preparing a pd-1/pd-l1 inhibitor.
The present invention relates to processes of prepa... |
|
|
Invention
|
Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 r... |
|
|
Invention
|
Bicyclic heterocycles as fgfr inhibitors.
The present invention relates to bicyclic heterocycles... |
|
|
Invention
|
Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma.
Th... |
|
|
Invention
|
Process and intermediates for preparing a jak inhibitor.
The present disclosure is related to pr... |
|
|
Invention
|
Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy.
Disclosed are combi... |
|
|
Invention
|
Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors.
The present application provid... |
|
|
Invention
|
Triazolopyrimidines as a2a / a2b inhibitors.
This application relates to compounds of Formula (I... |
|
|
Invention
|
Salts of a pim kinase inhibitor.
The present invention relates to salt forms of the Pim kinase i... |
|
|
Invention
|
Bicyclic amines as cdk2 inhibitors.
The present application provides bicyclic amines of Formula ... |
|
|
Invention
|
Bicyclic amines as cdk2 inhibitors. The present application provides bicyclic amines of Formula (... |
|
|
Invention
|
Pyrazoloquinoline kras inhibitors.
Disclosed are compounds of Formula I, methods of using the co... |
|
|
Invention
|
Salts of an fgfr inhibitor.
The present invention relates to salt forms of the Fibroblast Growth... |
|
|
Invention
|
Topical ruxolitinib foam.
The present disclosure is directed to foamable composition suitable fo... |
|
|
Invention
|
Topical ruxolitinib foam. 16-1816-18 fatty alcohols, and an emulsifier component. The present dis... |
|
|
Invention
|
Anti-cd73 antibodies and uses thereof.
Anti-CD73 antibodies are disclosed. Also disclosed are re... |
|
|
Invention
|
Macrocyclic kinase inhibitors.
The present application provides macrocyclic compounds that modul... |
|
|
Invention
|
Jak inhibitor with a vitamin d analog for treatment of skin diseases.
The present disclosure rel... |
|
|
Invention
|
Vinyl imidazole compounds as inhibitors of kras.
Disclosed are compounds of Formula I, methods o... |
|
|
Invention
|
Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp).... |
|
|
Invention
|
2-azabicyclo[2.2.1]heptane kras inhibitors.
Disclosed are compounds of Formula (I), methods of u... |
|
|
Invention
|
2-azabicyclo[2.2.1]heptane kras inhibitors. Disclosed are compounds of Formula (I), methods of us... |
|
|
Invention
|
Pyrrolidine kras inhibitors.
Disclosed are compounds of Formula (I), methods of using the compou... |
|
|
Invention
|
Cyclic urea kras inhibitors.
Disclosed are compounds of Formula (I), methods of using the compou... |
|
|
Invention
|
Pyrrolidine kras inhibitors. Disclosed are compounds of Formula (I), methods of using the compoun... |
|
|
Invention
|
Use of an anti-tgfbetar2/pd-1 bispecific antibody to treat cancer. The present disclosure describ... |
|
|
Invention
|
Use of an anti-tgfßr2/pd-1 bispecific antibody.
The present disclosure describes a bispecific an... |
|
|
Invention
|
Novel pd-1 binding domains.
The present disclosure relates to novel PD-1 binding domains that ha... |
|
|
Invention
|
Fused pyrazine derivatives as a2a / a2b inhibitors.
This application relates to compounds of For... |
|
|
Invention
|
Jak1 pathway inhibitors for the treatment of asthma.
This disclosure relates to JAK1 pathway inh... |
|
|
Invention
|
Bicyclic ureas as kinase inhibitors.
The present application provides bicyclic urea compounds th... |
|
|
Invention
|
Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active age... |
|
|
Invention
|
Jak1 pathway inhibitors for the treatment of vitiligo.
This disclosure relates to JAK1 pathway i... |
|
|
Invention
|
Combinations and uses thereof.
The present disclosure describes a pharmaceutical combination of ... |
|
|
Invention
|
Quinoline compounds as inhibitors of kras.
Disclosed are compounds of Formula I, methods of usin... |
|
|
Invention
|
Aminopyrazine diol compounds as pi3k-y inhibitors.
This application relates to compounds of Form... |
|
|
Invention
|
Formulations of an axl/mer inhibitor.
The present application relates to pharmaceutical formulat... |
|
2023
|
Invention
|
Pyrazolopyridine compounds and uses thereof.
Disclosed are compounds of Formula (I), methods of ... |
|
2022
|
Invention
|
Anti-b7-h4 antibodies and uses thereof.
Anti-B7-H4 antibodies are disclosed. Also disclosed are ... |
|
2010
|
G/S
|
Pharmaceutical preparations for use in the treatment of oncological, hematological and inflammato... |
